Market Cap 651.25B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 24.62
Forward PE 23.03
Profit Margin 28.46%
Debt to Equity Ratio 0.44
Volume 6,186,800
Avg Vol 8,082,050
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 71%
Beta 0.24
Analysts Strong Sell
Price Target $275.42

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Chag999
Chag999 Aug. 23 at 5:15 PM
$SLS and $JNJ - Interesting Updated on $JNJ Website
1 · Reply
Buy_SoFi
Buy_SoFi Aug. 23 at 3:42 PM
$TLTFF $MRK $JNJ $IBRX $CGON Excellent video! LOTS of exciting things happening at Theralase. Amazing future for the company, patients and the shareholders.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 23 at 3:36 PM
$SLS $JNJ Interesting Timing! J&J Walks Away From a CAR T With 100% Response Rates Johnson & Johnson has returned rights to investigational CAR T therapy prizlon-cel (prizloncabtagene autoleucel) to AbelZeta Pharma, ending a partnership for the large B cell lymphoma (LBCL) treatment. AbelZeta disclosed the reversion, effective July, in a Sunday release, which also noted FDA clearance of an IND application for the therapy in LBCL. J&J had secured global rights outside Greater China in May 2023 for $245 million upfront through its former Janssen subsidiary, alongside undisclosed development, regulatory, and sales milestone payments. ✌️🙏❤️‍🩹
1 · Reply
Outcomes
Outcomes Aug. 23 at 11:11 AM
$IBRX $MRNA $PFE $JNJ $MRK .....in other than cancer news, but same mRNA BAD news: https://x.com/CBSMornings/status/2091247789204226076?s=20
1 · Reply
Outcomes
Outcomes Aug. 23 at 10:22 AM
$IBRX $MRNA $MRK $PFE $JNJ ….new level of awareness going on since Moderna’s announcement. Some very knowledgeable people who have been on the sidelines/shadows now showing courage. Dr. PSS knows. Dr. Jim Kim knows. mRNA BAD. SAVE THE CHILDREN. https://x.com/robinmonotti/status/2091162270650777962?s=46
1 · Reply
Outcomes
Outcomes Aug. 22 at 8:09 PM
$IBRX $MRNA $MRK $PFE $JNJ …..mRNA BAD. Turbo-cancers’ Data. Outcomes. PSS knows. Dr. Kim knows. https://zenodo.org/records/18991296
0 · Reply
TroyTiger
TroyTiger Aug. 22 at 6:58 PM
$TGTX Thanks to a X/Twitter follower I can repost this >> I got it right 2 months ago. Now add $JAZZ, $SNY to $JNJ as possible suitors. >>
4 · Reply
Juhanialainen
Juhanialainen Aug. 22 at 12:09 PM
$SLS You heard it here first: $JNJ is going to buy GPS and $ABBV Tambiciclib. $15 B each. Done deal. Carry on.
USAEquityResearch
USAEquityResearch Aug. 22 at 9:46 AM
$JNJ 📊 USAEquityResearch ▲ 270.24 (+1.07%) Trend: Bullish 📈 RSI (14): 71.6 — overbought, extended, caution warranted MACD: bullish, above signal line and rising Volume: normal 📌 Key Levels Resistance: 273.41 | Support: 254.41 20-MA: 262.15 | 50-MA: 254.83 💼 Fundamentals Mkt Cap: $651.25B P/E (TTM): 31.4 | Fwd P/E: 22.0 FCF: $16.89B (7.01/sh) Total Debt: $49.04B D/E: 57.71 📉 Options (exp 2026-08-28) ATM IV: 24.8% | Skew: +1.0% (balanced) P/C Ratio: 1.05 ⚖️ Neutral Max Pain: 257.50 Call wall: 272.50 | Put wall: 270.00 Educational content only. Not financial advice.
0 · Reply
Gebinator
Gebinator Aug. 21 at 11:43 PM
$SLS Happy weekend to all longs! It's been a beautiful day on Canada's Sunshine Coast 🌞 This week, and today's market activity especially, gives us much optimism that something's afoot and coming down the pipe. If it is the long-awaited '80th event' - well, in many ways it feels to me a relief, but also sadly ironic the 80th REGAL patient's death will cause such excitement and action in the stock market. For this reason I used to hold a lot of resentment for the IDMC for not halting and unblinding REGAL sooner. But I've resigned to waiting on the 80th like everyone else, having faith that the REGAL FA will show extraordinary efficacy, statistical power, meaning and significance and that, in of itself, will help save and extend more lives over the long term. Those BPs in the running - $JNJ, $LLY, $ABBV, $MRK, etc. -- I'm sure they all want REGAL numbers and statistics as refined, unequivocal and significant as possible -- and that will benefit all parties concerned! Reminder 👇
0 · Reply
Latest News on JNJ
Johnson & Johnson Transcript: Investor update

Aug 3, 2026, 8:00 AM EDT - 20 days ago

Johnson & Johnson Transcript: Investor update


Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Aug 2, 2026, 8:00 AM EDT - 21 days ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

JNJ


Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:38 PM EDT - 24 days ago

Johnson & Johnson lowers 2026 profit forecast

JNJ


Explainer: Can J&J finally put the talc litigation behind it?

Jul 29, 2026, 12:01 PM EDT - 25 days ago

Explainer: Can J&J finally put the talc litigation behind it?

JNJ


Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 12:26 PM EDT - 26 days ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

JNJ


J&J offers $5.5bn to settle baby powder lawsuits

Jul 28, 2026, 12:31 AM EDT - 26 days ago

J&J offers $5.5bn to settle baby powder lawsuits

JNJ


DePuy Synthes Acquires Expanding Innovations™

Jul 16, 2026, 8:00 AM EDT - 5 weeks ago

DePuy Synthes Acquires Expanding Innovations™

JNJ


Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Earnings Call Transcript: Q2 2026


Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Slides: Q2 2026


Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Earnings release: Q2 2026


Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Quarterly report: Q2 2026


Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:35 AM EDT - 5 weeks ago

Johnson & Johnson Hikes Guidance, Stock Falls

JNJ


Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:33 AM EDT - 5 weeks ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

JNJ


The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 6 weeks ago

The Big 3: UNH, KO, JNJ

JNJ KO UNH


Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 2 months ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

JNJ


Chag999
Chag999 Aug. 23 at 5:15 PM
$SLS and $JNJ - Interesting Updated on $JNJ Website
1 · Reply
Buy_SoFi
Buy_SoFi Aug. 23 at 3:42 PM
$TLTFF $MRK $JNJ $IBRX $CGON Excellent video! LOTS of exciting things happening at Theralase. Amazing future for the company, patients and the shareholders.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 23 at 3:36 PM
$SLS $JNJ Interesting Timing! J&J Walks Away From a CAR T With 100% Response Rates Johnson & Johnson has returned rights to investigational CAR T therapy prizlon-cel (prizloncabtagene autoleucel) to AbelZeta Pharma, ending a partnership for the large B cell lymphoma (LBCL) treatment. AbelZeta disclosed the reversion, effective July, in a Sunday release, which also noted FDA clearance of an IND application for the therapy in LBCL. J&J had secured global rights outside Greater China in May 2023 for $245 million upfront through its former Janssen subsidiary, alongside undisclosed development, regulatory, and sales milestone payments. ✌️🙏❤️‍🩹
1 · Reply
Outcomes
Outcomes Aug. 23 at 11:11 AM
$IBRX $MRNA $PFE $JNJ $MRK .....in other than cancer news, but same mRNA BAD news: https://x.com/CBSMornings/status/2091247789204226076?s=20
1 · Reply
Outcomes
Outcomes Aug. 23 at 10:22 AM
$IBRX $MRNA $MRK $PFE $JNJ ….new level of awareness going on since Moderna’s announcement. Some very knowledgeable people who have been on the sidelines/shadows now showing courage. Dr. PSS knows. Dr. Jim Kim knows. mRNA BAD. SAVE THE CHILDREN. https://x.com/robinmonotti/status/2091162270650777962?s=46
1 · Reply
Outcomes
Outcomes Aug. 22 at 8:09 PM
$IBRX $MRNA $MRK $PFE $JNJ …..mRNA BAD. Turbo-cancers’ Data. Outcomes. PSS knows. Dr. Kim knows. https://zenodo.org/records/18991296
0 · Reply
TroyTiger
TroyTiger Aug. 22 at 6:58 PM
$TGTX Thanks to a X/Twitter follower I can repost this >> I got it right 2 months ago. Now add $JAZZ, $SNY to $JNJ as possible suitors. >>
4 · Reply
Juhanialainen
Juhanialainen Aug. 22 at 12:09 PM
$SLS You heard it here first: $JNJ is going to buy GPS and $ABBV Tambiciclib. $15 B each. Done deal. Carry on.
USAEquityResearch
USAEquityResearch Aug. 22 at 9:46 AM
$JNJ 📊 USAEquityResearch ▲ 270.24 (+1.07%) Trend: Bullish 📈 RSI (14): 71.6 — overbought, extended, caution warranted MACD: bullish, above signal line and rising Volume: normal 📌 Key Levels Resistance: 273.41 | Support: 254.41 20-MA: 262.15 | 50-MA: 254.83 💼 Fundamentals Mkt Cap: $651.25B P/E (TTM): 31.4 | Fwd P/E: 22.0 FCF: $16.89B (7.01/sh) Total Debt: $49.04B D/E: 57.71 📉 Options (exp 2026-08-28) ATM IV: 24.8% | Skew: +1.0% (balanced) P/C Ratio: 1.05 ⚖️ Neutral Max Pain: 257.50 Call wall: 272.50 | Put wall: 270.00 Educational content only. Not financial advice.
0 · Reply
Gebinator
Gebinator Aug. 21 at 11:43 PM
$SLS Happy weekend to all longs! It's been a beautiful day on Canada's Sunshine Coast 🌞 This week, and today's market activity especially, gives us much optimism that something's afoot and coming down the pipe. If it is the long-awaited '80th event' - well, in many ways it feels to me a relief, but also sadly ironic the 80th REGAL patient's death will cause such excitement and action in the stock market. For this reason I used to hold a lot of resentment for the IDMC for not halting and unblinding REGAL sooner. But I've resigned to waiting on the 80th like everyone else, having faith that the REGAL FA will show extraordinary efficacy, statistical power, meaning and significance and that, in of itself, will help save and extend more lives over the long term. Those BPs in the running - $JNJ, $LLY, $ABBV, $MRK, etc. -- I'm sure they all want REGAL numbers and statistics as refined, unequivocal and significant as possible -- and that will benefit all parties concerned! Reminder 👇
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 21 at 11:10 PM
$SLS Dr. Stergiou is a very Shrewd CEO. He/Sellas didn’t go in to a quiet period on July 7, 2026 if it was that far ought. Dr. Stergiou is a man with a master plan, Monday is a going to rude awakening for Shorts that has been talking trash about him for years. News will hit in waves and by EOM September 2026 Sellas won’t be a stand alone Co. but be part of $JNJ. Mark this post! ✌️🙏❤️‍🩹
0 · Reply
Outcomes
Outcomes Aug. 21 at 10:58 PM
$IBRX $MRNA $MRK $PFE $JNJ mRNA BAD. Covid jab: ‘Turbo-cancers’ Flu vax: botched trial PSS knows. https://x.com/jesslovesmjk/status/2090478010600218827?s=46
1 · Reply
Ryuk
Ryuk Aug. 21 at 10:28 PM
$JNJ $1.88 close. You're welcome.
0 · Reply
trachea
trachea Aug. 21 at 7:58 PM
$JNJ $SLS are you ok bro?👍😁🍀
0 · Reply
Johnmtnb2018
Johnmtnb2018 Aug. 21 at 7:58 PM
$SLS $JNJ BO Monday!
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 21 at 7:52 PM
2 heads are better than one? Care to make a guess for me to point out what I might be missing about #otlk? $MRNA $REGN $JNJ $SLS . Thank you all!
0 · Reply
Ryuk
Ryuk Aug. 21 at 5:21 PM
$JNJ $1.70
0 · Reply
Ryuk
Ryuk Aug. 21 at 4:24 PM
$JNJ $1.58
0 · Reply
TheChartiste
TheChartiste Aug. 21 at 4:12 PM
$JNJ steady climber from here
0 · Reply
Ryuk
Ryuk Aug. 21 at 3:28 PM
$JNJ $1.45
0 · Reply
Ryuk
Ryuk Aug. 21 at 3:26 PM
$JNJ Lotto Play: $270 puts at $0.33.
0 · Reply
Ryuk
Ryuk Aug. 21 at 3:19 PM
$JNJ Lotto Play: $272.50 puts at $1.25.
0 · Reply